Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Cost of Revenue (2017 - 2024)

Avalo Therapeutics (AVTX) has disclosed Cost of Revenue for 8 consecutive years, with $714000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Cost of Revenue rose 190.24% year-over-year to $714000.0, compared with a TTM value of $916000.0 through Sep 2024, down 56.87%, and an annual FY2023 reading of $1.3 million, down 62.61% over the prior year.
  • Cost of Revenue was $714000.0 for Q3 2024 at Avalo Therapeutics, up from $343000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $2.1 million in Q4 2020 and bottomed at -$221000.0 in Q4 2023.
  • Average Cost of Revenue over 5 years is $611437.8, with a median of $551000.0 recorded in 2023.
  • The sharpest move saw Cost of Revenue skyrocketed 1787.95% in 2022, then plummeted 135.7% in 2023.
  • Year by year, Cost of Revenue stood at $2.1 million in 2020, then crashed by 80.0% to $424000.0 in 2021, then surged by 45.99% to $619000.0 in 2022, then tumbled by 135.7% to -$221000.0 in 2023, then skyrocketed by 423.08% to $714000.0 in 2024.
  • Business Quant data shows Cost of Revenue for AVTX at $714000.0 in Q3 2024, $343000.0 in Q2 2024, and $80000.0 in Q1 2024.